Japan launches LEQEMBI Pen, a new at-home weekly injection for early Alzheimer's treatment.

Eisai and Biogen have launched LEQEMBI Pen in Japan, a subcutaneous formulation of the Alzheimer's drug lecanemab, allowing patients with early Alzheimer's to self-administer weekly injections at home. This new option complements the existing intravenous treatment, offering greater convenience and potentially reducing healthcare resource use. LEQEMBI targets toxic amyloid protofibrils and plaques to slow disease progression. The launch follows approvals in the US and other countries, aiming to improve patient flexibility and treatment adherence.

Biogen Inc (BIIB) shares are trading near their 52-week high of $254.87, currently priced at $250.59 as of Nov 13, 2026 06:31 WIB on Pluang. Despite a 1.11% decline in the past day, investor interest remains strong with 100% buy orders and a typical hold time of 111 days. This contrasts with the stock's 52-week low of $161.48, highlighting resilience in the health sector amid new product launches like the LEQEMBI Pen in Japan.